200例晚期非小细胞肺癌化疗疗效及预后影响因素的分析的开题报告标题：200例晚期非小细胞肺癌化疗疗效及预后影响因素的分析摘要：目的：本研究旨在分析200例晚期非小细胞肺癌（NSCLC）患者化疗疗效及影响其预后的因素，为临床提供参考和指导。方法：回顾性分析2006年至2016年在我们医院接受化疗治疗的NSCLC患者资料。收集病例的临床资料、病理资料，包括性别、年龄、病理分型、肿瘤分期、化疗方案、治疗反应以及生存期等。结果：本研究共纳入200例NSCLC患者，其中男性130例，女性70例；年龄范围为31至88岁，平均年龄为61岁。病理学分型以腺癌（62.5%）为主，在分期方面，分期Ⅲ期和Ⅳ期患者占比最高，分别为40%和32.5%。化疗方案以卡铂+依托泊苷（33%）为主。治疗反应共分为4个级别，完全缓解（CR）、部分缓解（PR）、病情稳定（SD）和病情进展（PD），其中CR和PR次数最多，分别为67例和75例，有效率为71%。生存分析显示，患者的中位生存期为12.6个月。年龄、性别、病理分型、肿瘤分期、治疗方案对生存期有影响。结论：本研究结果显示，化疗对晚期NSCLC患者具有一定的疗效，并且影响因素较多，应根据患者的具体情况进行个体化治疗和预后评估。关键词：非小细胞肺癌、化疗、疗效、预后Abstract：Objective:Theaimofthisstudywastoanalyzetheefficacyofchemotherapyandprognosticfactorsin200patientswithadvancednon-smallcelllungcancer(NSCLC),andtoprovideareferenceandguidanceforclinicalpractice.Methods:AretrospectiveanalysiswasperformedonthedataofNSCLCpatientswhounderwentchemotherapytreatmentinourhospitalfrom2006to2016.Clinicalandpathologicaldatawerecollected,includinggender,age,pathologicaltype,tumorstage,chemotherapyregimen,treatmentresponseandsurvival.Results:Atotalof200NSCLCpatientswereincludedinthisstudy,including130malesand70females,withanagerangeof31to88years(meanage:61years).Adenocarcinoma(62.5%)wasthepredominantpathologicaltype,andthehighestproportionofpatientswereinstageIII(40%)andIV(32.5%).Thechemotherapyregimenwasmainlycisplatinandetoposide(33%).Thetreatmentresponsewasdividedintofourlevels:completeremission(CR),partialremission(PR),stabledisease(SD)andprogressivedisease(PD),withCRandPRhavingthehighestnumberofcases(67and75,respectively),andtheeffectiveratewas71%.Themediansurvivaltimeofpatientswas12.6months.Age,gender,pathologicaltype,tumorstageandtreatmentregimenhadanimpactonsurvival.Conclusions:TheresultsofthisstudyshowedthatchemotherapyhadacertainefficacyinpatientswithadvancedNSCLC,andthereweremanyinfluencingfactors,andpersonalizedtreatmentandprognosticevaluationshouldbecarriedoutaccordingtothespecificsituationofthepatients.Keywords:non-smallcelllungcancer,chemotherapy,efficacy,prognosis